छोड़कर सामग्री पर जाएँ

AstraZeneca to buy vaccine developer Icosavax for up to $1.1 billion

  • द्वारा
  • Latest News

The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met.

Top 100 Best Sellers

Read More

​ The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met. The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी
en_USEnglish hi_INहिन्दी